 FOSTER CITY, Calif.--BUSINESS WIRE--Geron Corporation Nasdaq: GERN, a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses related to imetelstat, the Companys first-in-class telomerase inhibitor, are now available on Gerons website as well as to participants of the EHA2021 Virtual Congress. These poster presentations further support imetelstats differentiated approach to potentially target the malignant stem and p 